, Relations entre le taux de 5mC, 5hmC et pronostic des patients : utilité comme biomarqueur ? Plusieurs études ont reliées l'état de méthylation de l'ADN au pronostic des patients. Nous avons donc recherché si des variations significatives de 5mC et/ou 5hmC existaient entre les différents sous-groupes

, Ces taux plus élevés de 5hmC laissent supposer une dérégulation de la méthylation et déméthylation de l'ADN lorsque le pronostic est défavorable, c'est-à-dire que la cellule leucémique est plus agressive avec un potentiel de réplication plus important. On peut également supposer que cette hyperhydroxyméthylation de l'ADN est liée à une diminution focale des taux de 5mC, Nos résultats montrent une tendance à l'augmentation des taux de 5hmC lorsque le pronostic selon l'ELN est défavorable

M. De-cette, Figueroa (67) et ses collaborateurs ont montré qu'il existe des

, Acute Myeloid Leukemia -Cancer Stat Facts, 2019.

H. Döhner, D. J. Weisdorf, and C. D. Bloomfield, Acute Myeloid Leukemia, N Engl J Med, vol.373, issue.12, pp.1136-52, 2015.

L. I. Shlush, Age-related clonal hematopoiesis, Blood, vol.131, issue.5, pp.496-504, 201801.

F. Danlos, M. Papo, and J. Micol, L'hématopoïèse clonale : un concept émergent à la croisée des spécialités. Rev Médecine Interne, 2019.

J. P. Patel, M. Gönen, M. E. Figueroa, H. Fernandez, Z. Sun et al., Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia, N Engl J Med, vol.366, issue.12, pp.1079-89, 2012.

, Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia, N Engl J Med, vol.368, issue.22, pp.2059-74, 2013.

H. Döhner, E. Estey, D. Grimwade, S. Amadori, F. R. Appelbaum et al., Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, vol.129, pp.424-471, 2017.

C. Röllig and G. Ehninger, How I treat hyperleukocytosis in acute myeloid leukemia, Blood, vol.125, issue.21, pp.3246-52, 2015.

N. Lerolle, D. Borgel, and J. Diehl, Approche critique des critères diagnostiques de coagulation intravasculaire disséminée. Réanimation, vol.17, pp.348-54, 2008.

A. Kabel, . Zamzami, . Al-talhi, R. Al-dwila, and . Hamza, Acute myeloid leukemia: A focus on risk factors, clinical presentation, diagnosis and possible lines of management, vol.5, pp.62-69, 2017.

M. C. Béné, T. Nebe, P. Bettelheim, B. Buldini, H. Bumbea et al., Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10, Leukemia, vol.25, issue.4, pp.567-74, 2011.

I. Luquet, A. Bidet, W. Cuccuini, M. Lafage-pochitaloff, M. Mozziconacci et al., Place de la cytogénétique dans la prise en charge des leucémies aiguës myéloïdes : actualisation par le Groupe francophone de cytogénétique hématologique (GFCH), An Biol Clin, vol.74, issue.5, pp.535-581, 2016.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-405, 2016.

U. Creutzig, . Heuvel-eibrink-mm-van-den, B. Gibson, M. N. Dworzak, S. Adachi et al., Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, Blood, vol.120, issue.16, pp.3187-205, 2012.

L. Llopis, O. Nibourel, N. Boissel, P. Huchette, A. Renneville et al., Implication des mutations des gènes IDH1 et IDH2 dans les leucémies aiguës myéloïdes. Hématologie, vol.17, pp.132-176, 2011.

E. Papaemmanuil, M. Gerstung, L. Bullinger, V. I. Gaidzik, P. Paschka et al., Genomic Classification and Prognosis in Acute Myeloid Leukemia, N Engl J Med, vol.374, issue.23, pp.2209-2230, 2009.

J. M. Rowe and M. S. Tallman, How I treat acute myeloid leukemia, Blood, vol.116, issue.17, pp.3147-56, 2010.

G. Ossenkoppele and B. Löwenberg, How I treat the older patient with acute myeloid leukemia, Blood, vol.125, issue.5, pp.767-74, 2015.

J. Hu, Y. Liu, C. Wu, F. Xu, Z. Shen et al., Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia, Proc Natl Acad Sci, vol.106, issue.9, pp.3342-3349, 2009.

R. K. Hills, S. Castaigne, F. R. Appelbaum, J. Delaunay, S. Petersdorf et al., Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol, vol.15, issue.9, pp.986-96, 2014.

J. Prada-arismendy, J. C. Arroyave, and S. Röthlisberger, Molecular biomarkers in acute myeloid leukemia, Blood Rev, vol.31, issue.1, pp.63-76, 2017.

D. Zachari, A. Smith, and . Meissner, DNA methylation: roles in mammalian developmen, Nat Rev Genet, issue.14, pp.204-224, 2013.

K. M. Meldi and M. E. Figueroa, Cytosine modifications in myeloid malignancies, Pharmacol Ther, vol.152, pp.42-53, 2015.

W. Li and L. Xu, Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies, Oncol Res Treat, vol.42, issue.6, pp.309-327, 2019.

M. Kulis and M. Esteller, DNA Methylation and Cancer, Advances in Genetics, pp.27-56, 2010.

A. Vasanthakumar and L. A. Godley, 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy, Cancer Genet, vol.208, issue.5, pp.167-77, 2015.

P. M. Das and R. Singal, DNA methylation and cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.22, issue.22, pp.4632-4674, 2004.

S. Ecsedi, J. R. Rodríguez-aguilera, and H. Hernandez-vargas, Hydroxymethylcytosine (5hmC), or How to Identify Your Favorite Cell. Epigenomes, Jan, vol.5, issue.1, p.3, 2018.

C. E. Nestor, R. Ottaviano, J. Reddington, D. Sproul, D. Reinhardt et al., Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes, Genome Res, vol.22, issue.3, pp.467-77, 2012.

M. M. Dawlaty, K. Ganz, B. E. Powell, Y. Hu, S. Markoulaki et al., Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development, Cell Stem Cell, vol.9, issue.2, pp.166-75, 2011.

E. Pronier, A. C. Mokrani, H. Vasanthakumar, A. Simon, A. Da-costa-reis-monte-mor et al., Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors, Blood, vol.118, issue.9, pp.2551-2556, 2011.

T. Gu, F. Guo, H. Yang, H. Wu, G. Xu et al., The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes, Nature, vol.477, issue.7366, pp.606-616, 2011.

V. I. Gaidzik, R. F. Schlenk, P. Paschka, A. Stölzle, D. Späth et al., Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG), Blood, vol.121, issue.23, pp.4769-77, 2013.

S. Gross, R. A. Cairns, M. D. Minden, E. M. Driggers, M. A. Bittinger et al., Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations, J Exp Med, vol.207, issue.2, pp.339-383, 2010.

S. Weissmann, T. Alpermann, V. Grossmann, A. Kowarsch, N. Nadarajah et al., Landscape of TET2 mutations in acute myeloid leukemia, Leukemia, vol.26, issue.5, pp.934-976, 2012.

H. Huang, X. Jiang, Z. Li, Y. Li, C. Song et al., TET1 plays an essential oncogenic role in MLLrearranged leukemia, Proc Natl Acad Sci, vol.110, issue.29, pp.11994-12003, 2013.

M. E. Figueroa, O. Abdel-wahab, C. Lu, P. S. Ward, J. Patel et al., Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, vol.18, pp.553-67, 2010.

R. Rampal, A. Alkalin, J. Madzo, A. Vasanthakumar, E. Pronier et al., DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia, Cell Rep, vol.9, issue.5, pp.1841-55, 2014.

M. Guillermo and G. Guillermo, Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management, Am J Hematol, vol.93, issue.1, pp.129-176, 2017.

B. Chowdhury, A. Mcgovern, Y. Cui, S. R. Choudhury, I. Cho et al., The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells. Sci Rep, vol.5, p.9281, 2015.

B. Vet?, P. Szabó, C. Bacquet, A. Apró, E. Hathy et al., Inhibition of DNA methyltransferase leads to increased genomic 5-hydroxymethylcytosine levels in hematopoietic cells, FEBS Open Bio, vol.8, issue.4, pp.584-92, 2018.

R. Itzykson, O. Kosmider, T. Cluzeau, V. Mansat-de-mas, F. Dreyfus et al., Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias, Leukemia, vol.25, issue.7, pp.1147-52, 2011.

B. Sarah, N°4 Déc. 2018 : leucémies aiguës myéloblastiques(LAM) Inhibiteurs d'IDH1, vol.8

H. Hémato, , 2018.

, IDHIFA 50 mg, comprimé -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2019.

, Métabolisme du fer chez l'Homme, laboratoire d'hématologie cellulaire du CHU d'Angers

B. Singh, S. Arora, P. Agrawal, and S. K. Gupta, Hepcidin: A novel peptide hormone regulating iron metabolism, Clin Chim Acta, vol.412, issue.11, pp.823-853, 2011.

S. Park, O. Kosmider, F. Maloisel, B. Drenou, N. Chapuis et al., Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes, Haematologica, vol.104, issue.3, pp.497-504, 2019.

E. Pourcelot, Rôle du fer et des espèces réactives de l'oxygène dans la prolifération et la différenciation des leucémies aiguës myéloblastiques, 2013.

Y. Yu, Z. Kovacevic, and D. R. Richardson, Tuning Cell Cycle Regulation with an Iron Key. Cell Cycle, vol.6, pp.1982-94, 2007.

L. Scourzic, E. Mouly, and O. A. Bernard, TET proteins and the control of cytosine demethylation in cancer, Genome Med, vol.7, issue.1, p.9, 2015.

R. Yin, J. Mo, J. Dai, and H. Wang, Nickel(II) Inhibits Tet-Mediated 5-Methylcytosine Oxidation by High Affinity Displacement of the Cofactor Iron(II), ACS Chem Biol, vol.12, issue.6, pp.1494-1502, 2017.

. Expasy--cellosaurus, , 2019.

D. Grunwald, J. Mayol, and X. Ronot, Cycle cellulaire et cytométrie en flux

D. Cilloni, A. Renneville, F. Hermitte, R. K. Hills, S. Daly et al., Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.31, pp.5195-201, 2009.

. Laboratoire-d'hématologie-cellulaire-du-chu-d'angers, , 2019.

N. Le, The role of iron in cell cycle progression and the proliferation of neoplastic cells, Biochim Biophys Acta BBA -Rev Cancer, vol.1603, issue.1, pp.31-46, 2002.

Y. Jiang, J. Falk, J. M. Liu, D. Maciejewski, and J. P. , Global Methylome of Normal and Malignant Hematopoietic Stem Cells. Blood, vol.110, pp.2118-2118, 2007.

M. Foksinski, E. Zarakowska, D. Gackowski, M. Skonieczna, K. Gajda et al., Profiles of a broad spectrum of epigenetic DNA modifications in normal and malignant human cell lines: Proliferation rate is not the major factor responsible for the 5-hydroxymethyl-2?-deoxycytidine level in cultured cancerous cell lines. PLOS ONE, vol.12, p.188856, 2017.

R. C. Hider and A. V. Hoffbrand, The Role of Deferiprone in Iron Chelation, N Engl J Med, vol.379, issue.22, pp.2140-50, 2018.

. Pubchem, Ferric ammonium citrate, 2019.

W. Li and M. Liu, Distribution of 5-Hydroxymethylcytosine in Different Human Tissues, Journal of Nucleic Acids, 2011.

L. I. Kroeze, M. G. Aslanyan, T. N. Rooij-a-van,-koorenhof-scheele, M. Massop, and T. Carell, Characterization of acute myeloid leukemia based on levels of global hydroxymethylation, Blood, vol.124, issue.7, pp.1110-1118, 2014.

J. Ahn, H. Kim, Y. Kim, S. Lee, S. Ahn et al., 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia, Oncotarget, vol.8, issue.5, pp.8305-8319, 2016.

. Clinvar, , 2019.

Y. M. Xue, H. C. Cheng, J. H. Wang, W. Wang, and L. Miao, Cytosine 5-hydroxymethylation regulated kit gene expression in acute myeloid leukemia, J Biol Regul Homeost Agents, vol.33, issue.2, pp.345-53, 2019.

D. A. Russler-germain, D. H. Spencer, M. A. Young, T. L. Lamprecht, C. A. Miller et al., The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers, Cancer Cell, vol.25, issue.4, pp.442-54, 2014.

M. E. Figueroa, S. Lugthart, Y. Li, C. Erpelinck-verschueren, X. Deng et al., DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. Cancer Cell, vol.17, pp.13-27, 2010.